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Abstract
MicroRNAs (miRNAs) belong to a family of small non-coding RNAs (sncRNAs) playing important roles in human carcinogenesis. Multiple
investigations reported miRNAs aberrantly expressed in several cancers, including high-grade serous ovarian carcinoma (HGS-OvCa). Quantita-
tive PCR is widely used in studies investigating miRNA expression and the identification of reliable endogenous controls is crucial for proper
data normalization. In this study, we aimed to experimentally identify the most stable reference sncRNAs for normalization of miRNA qPCR
expression data in HGS-OvCa. Eleven putative reference sncRNAs for normalization (U6, SNORD48, miR-92a-3p, let-7a-5p, SNORD61,
SNORD72, SNORD68, miR-103a-3p, miR-423-3p, miR-191-5p, miR-16-5p) were analysed on a total of 75 HGS-OvCa and 30 normal tissues,
using a highly specific qPCR. Both the normal tissues considered to initiate HGS-OvCa malignant transformation, namely ovary and fallopian
tube epithelia, were included in our study. Stability of candidate endogenous controls was evaluated using an equivalence test and validated by
geNorm and NormFinder algorithms. Combining results from the three different statistical approaches, SNORD48 emerged as stably and equiv-
alently expressed between malignant and normal tissues. Among malignant samples, considering groups based on residual tumour, miR-191-
5p was identified as the most equivalent sncRNA. On the basis of our results, we support the use of SNORD48 as best reference sncRNA for rel-
ative quantification in miRNA expression studies between HGS-OvCa and normal controls, including the first time both the normal tissues sup-
posed to be HGS-OvCa progenitors. In addition, we recommend miR-191-5p as best reference sncRNA in miRNA expression studies with
prognostic intent on HGS-OvCa tissues.
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Introduction
Epithelial ovarian cancer is the fifth most common type of cancer in
women and the leading cause of mortality for gynaecological neo-
plasms, with high-grade serous carcinoma (HGS-OvCa) being the
most frequent and aggressive histological type [1]. The high mortality
rate of HGS-OvCa is because of the intrinsic biology of the disease
that remains largely undetected, leading to a delayed diagnosis of
patients presenting disseminated metastatic disease [2] and, conse-
quently, a 5-year survival rate of only 30% [3]. Recent investigations
report microRNAs (miRNAs) as important players in human
carcinogenesis and aberrantly expressed in several cancers, including
ovarian carcinoma tissues [4, 5]. Those small (19–25 nucleotides)
non-coding transcripts act as gene regulators, modulating post-tran-
scriptional activity of multiple target mRNAs (oncogenes or tumour
suppressor genes) by repression of translation or regulation of mRNA
degradation after targeting the 30 UTR [6, 7]. Recently, several papers
have identified HGS-OvCa-specific miRNA expression signatures as
promising novel biomarkers associated with diagnosis, prognosis
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and response to therapy [8, 9]. One of the most powerful and
sensitive technique available for miRNA expression analysis is quanti-
tative RT-PCR, which commonly uses relative quantification as a
strategy for data interpretation. In relative quantification, changes in
miRNA expression in a given sample are expressed relative to another
reference sample, after normalization using a stably expressed
endogenous reference simultaneously determined. In this kind of
study, similarly to mRNA expression analysis, the selection of valid
and reliable endogenous normalizers is critical to minimize technical
bias introduced at each step of miRNA retrotranscription and quantifi-
cation and to avoid misinterpretation of results. Recently, it has been
reported the recommendation to normalize target mRNA levels with
reference genes belonging to the same RNA class [10]. Consequently,
for miRNA expression normalization, the endogenous control genes
should belong to the small non-coding RNA family (sncRNA), such as
miRNA, small nuclear RNA (snRNA) and small nucleolar RNA
(snoRNA).
Currently, a proper endogenous control-based normalization strat-
egy to be used in miRNA qPCR studies on cancer tissues has not been
identified [11]. Moreover, there is a lack of consensus in the literature
on the most stably expressed endogenous controls that should be used
in HG-OvCa miRNA qPCR studies. Actually, most of the investigations
report arbitrarily chosen endogenous controls, including miRNA,
snRNA and snoRNA, without any experimental validation of their stabil-
ity. In addition, the large majority of these studies report U6 (alias
RNU6-1) as an endogenous reference, although its use is still contro-
versial, as a growing body of evidence demonstrate its high expression
instability across normal and tumour tissues [12, 13].
To fill this gap of knowledge, the present investigation aims at
identifying the most suitable sncRNAs as the endogenous controls
for miRNA expression normalization in a wide and well-characterized
cohort of HGS-OvCa tissues. Furthermore, as HGS-OvCa histogenesis
is still a matter of debate [14, 15], we aimed at validating the stability
of the proposed endogenous control sncRNAs in both normal ovarian
surface and fallopian tube epithelium, as normal tissues to be com-
pared with the cancer counterpart.
Materials and methods
Selection of candidate reference sncRNAs
The candidate endogenous sncRNAs were chosen based on the literature
suggesting their use for normalization of qPCR studies in HGS-OvCa tissue
samples, carrying out a Medline search using the MeSH terms ‘ovarian
cancer’/‘ovarian carcinoma’ and ‘microRNA’/‘miRNA’ and ‘real-time PCR’.
In addition, endogenous miRNA recommended from Exiqon (Woburn, MA,
USA), based on their stable and constitutive expression across different
cells and tissues, were included in our study [11, 16–18].
Patients cohorts
This study was performed following the Declaration of Helsinki set of
principles and approved by the Research Review Board- the Ethic
Committee- of the Spedali Civili, Brescia, Italy (study reference number:
NP1676). Written informed consent was obtained from all patients
enrolled. HGS-OvCa tissue samples were obtained from 75 patients
diagnosed and treated at the Division of Gynecologic Oncology of the
University of Brescia (Italy), between 2003 and 2013. Normal control
tissue samples were obtained from a total of 30 patients, undergoing
surgery for benign pathologies (Table 1). Details are reported in
Table S1.
RNA isolation, cDNA synthesis and quantitative
real-time PCR
Total RNA was extracted from tissue samples, homogenized with Tis-
sueLyser System (Qiagen), using TRIZOL reagent (Life Technologies,
Carlsbad, CA, USA) and further purified using RNeasy MiniElute Cleanup
kit (Qiagen, Germantown, MD, USA) with a modified protocol for co-
purification of small RNAs according to the manufacturer’s instructions.
RNA concentration and integrity was assessed as previously described
[19]. The miRCURY locked-nucleic-acid (LNA) Universal RT miRNA PCR
system (Exiqon) based on universal reverse transcription followed by
real-time PCR amplification with sncRNA-specific primers, was used for
first-strand cDNA synthesis and SYBR Green-based amplification.
Details are described in Table S2.
Statistical analysis
Stability of candidate endogenous miRNA was evaluated using two dif-
ferent software programs commonly used in the experimental validation
of reference genes, NormFinder [20] and geNorm [10]. Both algorithms
identify the most stable control gene in a given set of tissue samples
and determine the optimal number of references required for reliable
normalization of qPCR data.
Differences in sncRNA expression between groups were tested using
linear models on log-transformed sncRNA expression values, with P





n 75 15 15
Age at diagnosis
(mean years, range)








2342 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
values and confidence intervals (CIs) estimation based on ‘White-Huber’
heteroscedasticity corrected covariance matrices [21]. To account for
the presence of potential outliers, we fitted weighted least squares with
weights computed by M-estimation [22]. To test non-difference of
sncRNA expression among groups, we used the two one-sided test
(TOST) approach, a type of intersection union test [23]. Briefly an
‘equivalence range’ [eL,eU] is defined. The null hypothesis is set up so
that if the 90% CI for the parameter of interest (e.g. the difference
among group means) falls completely within the equivalence range, the
null hypothesis can be rejected. Two one-sided tests were conducted
for both boundaries of the range. The overall null hypothesis is rejected
at level a if the associated P-value for each of the individual hypotheses
is less than a (a = 0.05 in our analysis). Prior to conducting an equiva-
lent test, we must define an equivalence range, in which we can con-
sider the parameter of interest in the two groups to be substantively
equal. While no fixed objective rules exist to guide the choice of the
equivalence range because such choice may depend on substantive
considerations, Wellek [24] suggested a strict tolerance value for a two
sample t-test of 0.36 on log scale, and we decided to adopt this latest
criteria in our data analysis.
Statistical analysis were performed with R [25] with additional pack-
age robustbase [26].
Results
Identification of reference sncRNAs
According to our Medline search criteria, we found 114 papers pub-
lished from November 2007 to August 2015. Within these reports, we
removed from analysis papers evaluating gene expression and geno-
typing studies, as well as miRNA expression studies performed on
cell cultures, formalin-fixed paraffin-embedded tissues or plasma/
serum/urines. Additional articles were excluded because full text was
not available in the English language. The remaining 29 papers
focused on miRNA expression evaluation in fresh frozen ovarian
tumour tissues by real-time PCR, using the following sncRNAs for
data normalization, alone or in combination of two or three: U6 (25
times), SNORD48 (two times), miR-92a-3p (one time), let-7a-5p (one
time), SNORD61 (one time), SNORD72 (one time), SNORD68 (one
time). This panel of seven potential endogenous controls derived
from the literature was integrated with four additional reference miR-
NAs, miR-103a-3p, miR-423-3p, miR-191-5p and miR-16-5p,
selected and validated from Exiqon for normalization of miRNA
expression levels in human tissue samples during real-time PCR anal-
ysis (Table S1).
Expression of candidate reference sncRNAs
Quantitative real-time PCR was performed on 75 HGS-OvCa, 15 nor-
mal luminal fallopian tube and 10 normal ovarian surface epithelia
samples (representative of 15 patients) to assess the expression pat-
tern of the 11 selected reference sncRNAs. All RNA samples isolated
from malignant and normal specimens met the criteria of purity and
integrity defined by A260/280 ratio (mean  S.D., 2  0.06) and
RIN values (RIN ≥ 8). All RNA samples were verified to be free of any
DNA contamination, by analysis of minus-reverse transcriptase
(‘-RT’) controls in real-time RT-PCR experiments (Table S2). For the
quantitative comparison of investigated candidate reference sncRNAs,
the raw Cq values were converted to CNRQ, a normalization proce-
dure which removes variations related to different cDNA starting
quantities and correct for run-to-run variation using an internal con-
trol sample [27], and log-transformed before statistical analysis. All
candidate reference sncRNAs were expressed in abundance both in
normal and in cancer tissues, with substantial higher spread in malig-
nant samples compared with non-malignant ones (Fig. 1). The
sncRNAs showing the higher interquartile-range (IQR) was miR-
103a-3p (IQR = 2.05), while miR-191-5p showed the smallest
(IQR = 0.92). Melting curve analysis confirmed the specificity of the
PCR products, for each primer set tested. No amplification was
detectable for each ‘no template control’ sample included in each
assay run for each sncRNA primer set.
Applying the TOST method equates at computing (1-2a)% CI
(90% when a = 0.05) for the contrast of interest (D = difference
between group means) and comparing it to the [eL,eU] range, if the CI
is fully included in the equivalence range the null hypothesis of non-
equivalence can be rejected. Table 2 shows 90% CIs for all the con-
trasts of interest and the P values as well as an indicator of null
hypothesis rejection based on |e| = 0.36. Accordingly, considering
the difference in sncRNA expression between malignant and non-
malignant samples, all sncRNA were substantially varying but
SNORD48, whose ratio of the two groups averages (0.282,+0.317)
falls within the fixed equivalence range. Moreover, we performed the
Fig. 1 Expression levels of candidate reference sncRNAs in HGS-OvCa
(hatched boxes) and normal (open boxes) tissues. Values are given as
calibrated normalized relative quantities (CNRQ). Boxes indicate IQR for
the data of unmatched samples in each group. Error bars represent
range of values.
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same analysis of statistical equivalence considering only the tumour
sample cohort, grouped based on residual tumour (RT). Among
malignant samples considering groups based on RT (RT = 0 versus
RT > 0), miR-191-5p emerged as the most equivalent sncRNA
(0.232,+0.358).
Analysis of candidate reference sncRNAs
expression stability
GeNorm and NormFinder software programs were used to compare
and rank the 11 potential reference sncRNAs on the basis of their sta-
bility across tumour and normal tissue samples. According to the
gene stability M value provided by geNorm, candidate reference
sncRNAs were ranked from the least stable (highest M value) to the
most stable (lowest M value). As an M value of 1.5 was defined as the
upper limit for candidate reference, and 0.5 was the M value typically
observed for stably expressed reference genes in homogeneous sam-
ple groups, values between 0.5 and 1 were considered as a character-
istic when evaluating endogenous controls on heterogeneous
samples like cancer and normal tissues [27]. As shown in Figure 2A,
all the studied sncRNAs achieved an overall medium to low expres-
sion stability, with M values ranging from 0.8 for let-7a-5p and miR-
103a-3p to 1.6 for miR-16-5p (average geNorm M ≥ 1.2). Accord-
ingly, let-7a-5p, miR-103a-3p and miR423-3p were identified as the
most stable sncRNAs in our panel of 75 HGS-OvCa and 30 normal tis-
sues, followed by miR-191-5p and SNORD48. In addition to the gen-
erated M value, geNorm software program calculates the optimal
number of sncRNAs required for a reliable normalization of qPCR
data, based on the variable V as the pairwise variation between
sequential normalization factors. Taking 0.15 as the cut-off value
below which the inclusion of an additional reference gene is not
required [10], the optimal number of reference sncRNAs was seven
(Fig. 2B). It must be pointed out that the proposed 0.15 value should
not be taken as a strict cut-off, but rather as a guidance for the calcu-
lation of the optimal number of references. In our experimental sys-
tem, the observed trend of changing V values when using additional
sncRNAs reveals that the highest decrease in variation was achieved
with the five most stable sncRNAs, in line with previous studies sug-
gesting that a proper normalization strategy for relative gene quantifi-
cation should include at least three to five endogenous references
[10]. The results generated from geNorm were compared and vali-
dated using NormFinder software program, whose algorithm rank the
set of candidate normalization genes according to their expression
stability. NormFinder identified SNORD48 as the best endogenous ref-
erence sncRNA, strictly followed by let-7a-5p and miR-191-5p, con-
sistent with geNorm analysis which ranked let-7a-5p, miR-191-5p
and SNORD48 among the fifth most stable sncRNAs (Table 3). Nota-
bly, U6, the reference sncRNA most frequently used as normalizer,
was ranked poorly in both analysis. Both geNorm and NormFinder
analysis were also in considerably closer agreement in the identifica-
tion of miR-16-5p, miR-92a-3p and SNORD72 as the least stable
sncRNAs in our cohort of samples.
In silico validation of candidate reference
sncRNAs using RNA-Seq data
To validate the stability of our candidate invariant sncRNAs, we per-
formed the same analysis of statistical equivalence on RNA-Seq data,
Table 2 Log-fold changes in reference sncRNA expression between HGS-OvCa and normal control samples, and among non-residual tumour
and residual tumour (90% confidence intervals; P values for linear models; * null hypothesis of non-equivalence rejected; [eL,eU] =
[0.36,0.36])
sncRNA
HGS-OvCa versus normal control RT = 0 versus RT > 0
Log FC 90% CI P-value Log FC 90% CI P-value
miR-16-5p 1.87 2.36;1.38 <0.001 0.16 0.43;0.11 0.328
miR-191-5p 0.10 0.44;0.24 0.625 0.06 0.23;0.36* 0.725
miR-423-3p 0.21 0.18;0.59 0.375 0.60 0.04;1.15 0.087
let-7a-5p 0.20 0.59;0.19 0.401 0.48 0.01;0.98 0.108
miR-103a-3p 0.15 0.60;0.31 0.601 0.28 0.35;0.90 0.465
miR-92a-3p 1.89 2.23;1.55 <0.001 0.40 0.005;0.80 0.096
SNORD68 0.23 0.55;0.09 0.229 0.28 0.14;0.71 0.274
SNORD61 0.33 0.08;0.74 0.190 0.05 0.42;0.32 0.828
SNORD72 1.21 0.80;1.63 <0.001 0.25 0.25;0.74 0.408
SNORD48 0.02 0.28;0.32* 0.924 0.25 0.14;0.64 0.287
U6 0.53 0.84;0.23 0.003 0.56 0.06;1.06 0.066
2344 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
based upon level 3 data generated by the TCGA research network
(http://cancergenome.nih.gov/). RNA-Seq data regarding 292 stage
III-IV HGS-OvCa snap-frozen tissues were available for analysis, with
similar clinic-pathologic characteristics compared with our cohort of
samples. Among malignant samples, considering groups based on
RT (RT = 0 versus RT > 0), miR-191-5p was confirmed to be the
most equivalent sncRNA (0.034,+0.231), as shown in Table 4.
Conversely, only six normal fallopian tube and four normal ovary
RNA-Seq data were present in the TCGA database and no information
about sample collection (i.e. macrodissected snap-frozen biopsies or
epithelial brushings) and tissue composition (i.e. epithelial purity)
was provided. Due to this lack of information, we were prevented to
perform the analysis of statistical equivalence on healthy tissue RNA-
Seq data.
Discussion
Quantitative PCR is generally accepted as gold standard for miRNA
measurement, and according to the guidelines for quality control and
standardization of qPCR experiments, selection of reliable endoge-
nous normalizer is a critical aspect to be considered for interpretation
of data. Similarly to mRNA expression analysis, the choice of refer-
ence genes for miRNA qPCR data normalization has a great impact
on the study outcome, as different normalization strategies can lead
to different interpretation of data resulting in ambiguous biological
conclusions [28].
As already postulated, miRNA may act ‘in cascade’ over several
mRNA genes, regulating multiple target within the same pathway,
thus small changes in miRNA expression could have important con-
sequences for a given cellular function [29]. Accordingly, the valida-
tion of endogenous normalizers is even more critical for miRNA qPCR
experiments, considering that relatively small differences in miRNA
expression may be biologically and clinically significant.
To date, no consensus strategy has been reached on the optimal
normalization for miRNA expression studies, and irrespective of the
guidelines suggesting a validation screening test on a subset of sam-
ples under analysis, endogenous references continue to be arbitrarily
chosen without any experimental evidence. To our knowledge, no val-
idated endogenous references have been identified for normalization
of miRNA expression data in ovarian cancer tissues. Confirming this
report, our comprehensive MEDLINE search of miRNA expression
studies published between 2007 and the middle of 2015 showed that
there was no uniform opinion on which reference should be used for
reliable normalization in HGS-OvCa samples. On the basis of the liter-
ature review, a total of seven sncRNAs were identified as putative ref-
erences for miRNA expression studies in ovarian cancer tissues.
Almost all of the published studies (25 out of 29) reported U6 as the
Fig. 2 geNorm output charts. (A) Average
expression stability value (M) of reference
sncRNAs calculated at each step during
stepwise exclusion of the least stable
expressed reference. Starting from the
least stable at the left, the sncRNA are
ranked according to increasing expression
stability, ending with the two most stable
sncRNA on the right. (B) Normalization
factor based on the pairwise variation (V),
representing the levels of variation in
average reference sncRNA stability with
the sequential addition of each reference
to the equation.
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reference of choice, while other sncRNAs, such as SNORD48, miR-
92a-3p, let-7a-5p, SNORD61, SNORD72 and SNORD68, have been
evaluated alone or in combination with U6 in the remaining papers.
To increase the number of potential endogenous sncRNAs to be eval-
uated in our cohort of 75 HGS-OvCa and 30 normal tissues, we
decided to adopt a combination strategy integrating data from the lit-
erature with the following panel of reference sncRNAs: miR-103a-3p,
miR-423-3p, miR-191-5p and miR-16-5p. They have been reported to
be constitutively expressed in a variety of normal and pathological tis-
sues, and validated from Exiqon for normalization of miRNA expres-
sion levels during real-time PCR analysis. None of these potential
endogenous controls had been previously evaluated in ovarian tissue
samples. The particular design of our study has been characterized
by several features, including: (i) wide cohort of snap-frozen tumour
tissue samples of HGS histological type, the most frequent and
aggressive ovarian cancer, belonging to a single institution, (ii) inclu-
sion of both ovarian surface and fallopian tube epithelia, as source of
normal control tissues, (iii) stringent quality control of isolated total
RNA, (iv) careful selection of putative reference sncRNAs, combining
a Medline search result and validated endogenous controls from Exi-
qon, (v) use of optimized Exiqon primer sets with LNA technology,
maximizing sensitivity and specificity in detecting sncRNA amplicons,
(vi) qPCR performed with SYBR Green technology, that is cost-effec-
tive and easy to apply in every laboratory setting, (vii) use of an inter-
run calibration sample, that showed an optimal correlation in sncRNA
expression among all plates and (viii) experiments performed in tripli-
cate for every sncRNA and every sample.
As known, reference genes are characterized by a stable expres-
sion across various samples and their use as normalizer in gene
expression studies can correct for experimental variations related to
sampling procedures, RNA extraction and RT efficiency. Besides, reli-
able quantification of miRNA expression levels faces some method-
ological problems, mainly related to the small size of mature miRNAs,
their relatively low abundance in human tissues and the high degree
of homology between miRNA family members [30]. Accordingly, the
choice of an appropriate detection system is an essential starting
point to obtain accurate results. One of the strengths of our experi-
mental method is the application of the Exiqon technology to RNA
samples, that quantify miRNA expression in a two-step PCR process
of modified RT-PCR, followed by a qPCR. In particular, starting from
total RNA, a universal transcription system provided template for all
mature miRNAs, overcoming the need for miRNA-specific reverse
transcription whose efficiency can vary among different miRNAs.
Both PCR amplification primers were miRNA-specific and chemically
modified in the ribose moiety of nucleotides to stabilize the conforma-
tion of the sugar groups [31], according to the Exiqon technology.
The conformation of LNA oligos resulted in enhanced hybridization
properties and increased sensitivity and specificity in detection of
scnRNAs. Moreover, the RT mechanism allowed the amplification of
mature miRNA only, without amplification of pre-miRNA whose inter-
action with oligos is prevented by the presence of the loop.
The aforementioned exceptional sensitivity, specificity and accu-
racy of the Exiqon qRT-PCR system have recently been confirmed by
Mestdagh et al. in the widest peer-reviewed investigation of miRNA
profiling platforms performed to date [31].
The second strength of our investigation relies on the use of both
the normal tissues suggested to be the initiating points of the HGS-
OvCa carcinogenetic process. Indeed, there has been increasing evi-
dence that HGS-OvCa might originate in oviductal fimbriae and metas-
tasize to the ovary [14], but the alternative hypothesis assuming that
ovarian carcinomas may originate within ovarian stroma in inclusion
cysts lined by ovarian surface epithelium is still under consideration
Table 4 Statistical equivalence analysis of candidate reference
sncRNA expression among non-residual tumour and residual
tumour HGS-OvCa tissues, quantified using RNA-Seq technology
sncRNA
HGS-OvCa RT = 0 versus RT > 0
Estimate 90% CI Width CI
miR-16-5p 0.0623 0.14;0.27 0.21
miR-191-5p 0.0989 0.03;0.23 0.13
miR-423-3p 0.1295 0.02;0.24 0.11
let-7a-5p 0.0828 0.17;0.33 0.25
miR-103a-3p 0.1493 0.09;0.38 0.24
miR-92a-3p 0.1696 0.02;0.35 0.19
SNORD68 0.0635 0.08;0.21 0.14
SNORD61 1.7428 2.83;0.65 1.09
SNORD72 1.2144 2.28;0.14 1.06
SNORD48 0.0817 0.08;0.25 0.17
U6 0.1678 0.004;0.38 0.22
Table 3 Candidate sncRNAs reference listed by their expression
stability according to the NormFinder software program
Ranking
order
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[32, 33]. Given these assumptions, our choice to include in the present
experimental setting both the putative normal controls for HGS-OvCa
represents an innovative approach, as ovarian and fallopian tube
epithelia have been poorly investigated together as normal controls in
previously reported HGS-OvCa gene expression studies. Moreover, our
approach represents an important point to obtain reliable expression
data on reference and eventually target sncRNAs, comparing HGS-
OvCa and its dually suggested normal counterpart.
To determine the best performing reference sncRNAs, we anal-
ysed our results with geNorm and NormFinder software programs,
two algorithms commonly used in gene expression studies and
specifically developed for reference gene evaluation and selection
[10, 20]. While geNorm indicated let-7a-5p, miR-103a-3p, miR-423-
3p, miR-191-5p and SNORD48 as the four most stably expressed
reference sncRNAs, NormFinder identified SNORD48, strictly fol-
lowed by let-7a-5p and miR-191-5p, as the three sncRNAs with the
best stability. However, the previously performed statistical analysis
on miRNA expression of our cohort of samples revealed that only
SNORD48 and miR-191-5p showed a significant equivalent expres-
sion in malignant versus non-malignant ovarian tissues or among
malignant samples grouped according to RT respectively. The same
powerful parametric approach has been recently reported by our
group, as a reliable tool to identify optimal reference genes for gene
expression normalization in endometrial cancer tissues [19]. Let-7a-
5p, although highly ranked by NormFinder and indicated among the
most stable reference genes in geNorm analysis, did not fulfil the
strict criteria of equivalency established by our statistical approach.
In this context, it is not advisable to blindly accept the best combina-
tion suggested by geNorm and NormFinder, as both algorithms
included sncRNAs showing differences in expression level between
normal and ovarian tumour tissues. Actually, combining the results
from the powerful statistical analysis and the expression stability
performed on the expression level of 11 candidate reference
sncRNAs, SNORD48 consistently emerged as the most stably
expressed sncRNA, regardless of sample type, to be used as nor-
malizer for relative miRNA quantification in HGS-OvCa samples ver-
sus normal controls. Notably, SNORD48 was already reported
among the most stably expressed sncRNAs in endometrial cancer
and renal cell carcinoma tissues [13, 34]. Conversely, U6, the most
commonly reported normalization sncRNAs for miRNA expression
studies, did not fulfil the criteria of constant expression between our
cohorts of normal and tumour samples, as already described for
other malignancies [11, 12, 17].
The second reference sncRNA resulted from our statistical anal-
ysis, confirmed to be equivalent within the group of tumour sam-
ples regardless of RT, was miR-191-5p. It is noteworthy that RT is
considered the most informative prognostic factor in advanced-
stage HGS-OvCa [35]. Given this assumption, miR-191-5p should
be recommended as reference sncRNA in miRNA expression stud-
ies with prognostic intent of HGS-OvCa tissues. Moreover, miR-
191-5p equivalent expression among HGS-OvCa tissues was suc-
cessfully validated by a further in silico analysis on RNA-Seq data,
available at TCGA. This additional validation strengthens our results,
as RNA-Seq technology provides a precise and accurate quantifica-
tion of transcript levels.
To the best of our knowledge, the current investigation reports the
first evaluation of a panel of putative reference sncRNAs in HGS-OvCa
tissue samples, the most frequent ovarian carcinoma histotype, using
either commonly reported software programs for gene expression nor-
malization or a novel powerful statistical approach. Taking our findings
together, the present study proposes, for the first time, SNORD48 as
the best reference sncRNA for relative quantification in miRNA expres-
sion studies comparing HGS-OvCa tissues and normal controls. Impor-
tantly, this is also the first study evaluating and validating the
equivalency and the stability of SNORD48 expression, other than in
tumour samples, in both the normal tissues considered to initiate the
malignant transformation. Finally, this is the first report supporting the
use of miR-191-5p in HGS-OvCa tissues with different RT, in agreement
with results provided by Exiqon regarding other solid malignancies.
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